Compounds > (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride
Page last updated: 2024-11-08

(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride and Alloxan Diabetes

(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride has been researched along with Alloxan Diabetes in 1 studies

(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride: A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Koga, K1
Honda, K1
Ando, S1
Harasawa, I1
Kamiya, HO1
Takano, Y1

Other Studies

1 other study available for (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride and Alloxan Diabetes

ArticleYear
Intrathecal clonidine inhibits mechanical allodynia via activation of the spinal muscarinic M1 receptor in streptozotocin-induced diabetic mice.
    European journal of pharmacology, 2004, Nov-28, Volume: 505, Issue:1-3

    Topics: (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; Analgesics; Animals; Atropine;

2004